Table 1.
Main clinical features of subjects under study
| Variable | Median (IQR) or percentage |
| Males (%) | 68.0 |
| Age (years) | 60 (52–66) |
| Body mass index (kg/m2) | 29.3 (26.6–32.9) |
| Waist circumference (cm) | 100 (94–109) |
| HbA1c (mmol/mol) (%) |
49 (44–56) 6.6 (6.2–7.3) |
| Fasting plasma glucose (mmol/L) | 7.0 (6.2–7.9) |
| 2-hour OGTT plasma glucose (mmol/L) | 12.9 (10.4–16.0) |
| LDL cholesterol (mmol/L) | 2.99 (2.41–3.58) |
| HDL cholesterol (mmol/L) | 1.14 (0.96–1.34) |
| Triglycerides (mmol/L) | 1.39 (1.03–2.0) |
| Statins (%) | 20.5 |
| Hypercholesterolemia (%) | 96.5 |
| Systolic blood pressure (mm Hg) | 134 (120–145) |
| Diastolic blood pressure (mm Hg) | 80 (80–90) |
| Antihypertensive drugs (%) | 56.8 |
| Hypertension (%) | 76.7 |
| eGFR (mL/min/1.73 m2) | 81.7 (70.8–94.1) |
| Antiplatelet or anticoagulant drugs (%) | 16.6 |
| Smokers (current/prior) (%) | 50.5 |
| Insulin sensitivity (µmol/min/m2 BSA) | 605 (380–874) |
| Beta-cell function—derivative control (pmol/m2 BSA/(mmol/L/min) |
444 (51–945) |
| Beta-cell function—proportional control (pmol/m2 BSA)/(mmol/L/min) |
47 (25–76) |
BSA, body surface area; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OGTT, oral glucose tolerance test.